Skip to main content

Bet on "BET = Biotech, Energy and Technology"?

My family and friends know that I like to take small bets almost on any topic. They also know that I win most of them. I did lose  big one with one of my colleague on Hillary vs Trump (no one would have imagined Trump would win except may be few folks like my colleague Arun). I ended up buying lunch for my colleagues for losing the bet. Investing is somewhat like betting. Depending on analysis and confidence, one is really making bets on companies doing well (or not) and investing (aka making bets) on stock prices going up (or down). Markets being at all time high, one must be wondering: Are there any sectors which are still worth making bets? Based on my analysis there are still opportunities in three of my favorite sectors - Biotech, Energy and Technology. In today's world of acronyms like FANG, I decided to call these as "BET". Let's look at why these three sectors?
Biotech: Two years back our family went thru experience on cancer. Since then, I have been doing quite a bit of reading on biotech field. I am reading The Emperor of All Maladies as well as follow various trials and FDA submissions. This field is really on cusp on major break thru for treatments for many fatal and rare diseases as well a finally some kind of cure for cancer. Last week Barrons even had cover-story on Gene Therapy With phase 3 trails for CAR-T, Gene Editing, Personalized medicines, world of cure is going to significantly change in 10 years. And biotech companies are leading the way. On investing side, this field is really brimming with activities with startups, big biotech companies as well pharma companies trying to transform into biotech companies (e.g Gilead buying Kite for $12B). Trial results and FDA decisions being "binary" event, one needs to be really brave, knowledgeable and lucky to make investing decisions. With this backdrop, here are my picks. Biotech ETF (IBB $330), Biogen (BIIB $320), Zogenix (ZGNX $38), Newline (NLNK $10), Regenxbio (RGNX $32). Most of these are extremely risky so best way to get exposure to biotech would be thru ETF (IBB)
Energy: With oil finally settling up above $50, I still stand behind my hypothesis that Energy stocks would have repeat of 2H of 2016 as I covered in my previous blog "It's time to get some Energy" So to avoid repeating myself, just check out my previous blog.
Technology: Outside of FANG, there is vast world of technology. So while FANG stocks are up significantly, there are still opportunities to grab. Personally I like small to mid-cap tech companies which are on upswing. With tax reforms almost here, tech companies are going to significantly benefit from worldwide economic growth as well as favorable repatriation rates. With trillions coming back to US, big tech companies would be on acquisition spree in next 2 years. Whom they are going to acquire? small to mid-cap companies to close portfolio gaps. Here are some picks: Nutanix (NTNX $22), AMD (AMD $13), Blackberry (BB from Oct 16, $10-11), FireEye (FEYE $17), Cloudera (CLDR $16), ServiceNow (NOW $100). With semiconductors back in action, SMH ($90) could be worth a look.
October is always tricky month - there are always surprises in Oct like political, economical as well as investing world. So to avoid getting caught in these surprises, I would recommend let the third quarter earnings season play out. It would give good indication on how companies in all three sectors have performed in Q3 and confidence level their CEOs are projecting, Then decide to do your own analysis and invest. Just don't "bet" based on my analysis!
It's also time to celebrate Holidays - starting with Diwali all the way to New Year! So enjoy the holidays with your family and friends!

Comments

Popular posts from this blog

Clicks to Tokens: Will 2026 Echo 1998's Boom or 2000's Bust?

My "blogging" was in hibernation last 8 months due to my self-imposed restraint given the environment as well as built-in inertia to get started despite so many interesting events and markets reaching all time highs after taking a big dump around "Liberation Day" in Apr...Around that time I had the blog ready that it would be repeat of Mar/Apr 2020 panic and recovery during onset of Covid Pandemic. The hunch happened to be correct and I was glad that I could keep and take some positions which I am still holding especially around AI theme. But that was then...as 2025 is about to wrap up in 10+ weeks, let's look at what's in store for rest of 2025 and 2026. And what's better time than to start writing again just before one of the most important week on the calendar with multiple key events coming up next week... Fed meeting to decide the course of interest rates - it's almost guaranteed that Fed will cut rates by 25 basis points (2nd time in 2025) and...

2026: The Year of Convergence – Melt-up, Moonshots, or Mid-cycle Correction?

Happy New Year! After another period of self-imposed hibernation from the blog—partly due to the festivals, travel, intertia and partly to watch the dust settle on a chaotic 2025—I decided to use the quiet of this New Year’s morning to finally reboot.  Looking back at my October post,  “Clicks to Tokens,”  the hunch about the AI theme held firm. We spent much of 2025 debating whether we were in 1998 or 2000. As we enter 2026, the answer seems to be "neither and both." We have the roaring optimism of the 1920s fueled by "Silicon Spirits," but with the high-speed volatility of the 2020s. So, as the calendar flips, what is in store for 2026? Markets may experience melt-up (S&P touching 8000),  with some moonshots (like SpaceX and OpenAI) IPOs or even see mid-cycle correction bringing down S&P to 6000. That's a wide range and will be decided by Four R's... Here are my thoughts on the " Four R’s ":  Rates, Robots, Rotations, and Real Assets. 1. ...

Stree-Dhan vs. Oracle of Omaha!

Happy February! After another brief hibernation from the blog—partly to digest the early year volatility and partly to observe the shifting sands of global liquidity—it’s time to look at some fascinating disconnects in the market. Lately, I’ve been thinking about the "Unbeatable Asset Class." No, I’m not talking about the S&P 500 or Nvidia. I’m talking about a collective force that has quietly outperformed the "Oracle of Omaha" for over two decades. 1. The Golden Saree: Indian Women vs. Warren Buffett If you look at the performance of Berkshire Hathaway (BRK-B) since the launch of the GLD ETF (the first gold ETF) in late 2004, you’ll find a startling reality. While Buffett is the gold standard of value investing, the "Gold Standard" itself—specifically in the hands of Indian households—has been a formidable rival. Data shows that since the inception of the GLD ETF in November 2004, the total return on Gold has actually surpassed Berkshire Hathaway. I...